CENTEK: Subsidiary Shandong Huasu Succinic Acid Metoprolol Raw Material Drug Approved for Market Launch

CENTEK announced that its subsidiary Shandong Huasu Pharmaceutical Co., Ltd.'s "Succinic Acid Metoprolol Active Pharmaceutical Ingredient" has passed the technical review by the National Medical Products Administration's Drug Evaluation Center and has received the "Approval Notice for the Market Application of Chemical Active Pharmaceutical Ingredients" issued by the National Medical Products Administration. The approval for this active pharmaceutical ingredient provides a stable source of raw materials for the company's research on succinic acid metoprolol sustained-release capsules, positively impacting the company's operating performance

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.